Business Wire

Western Provident Association Deploys Topdown INTOUCH SaaS CCM Solution to Optimize Healthcare Customer Communications

13.4.2022 16:00:00 EEST | Business Wire | Press release

Share

Western Provident Association (WPA), a leading not-for-profit health insurance company and Top Down Systems Corporation (Topdown), a best-of-breed Customer Communication Management, CCM, software company announced today that they will deploy the Topdown INTOUCH solution across WPA’s customer communications operations to improve customer experience, increase productivity, and reduce costs.

Organizations across industries today are challenged with managing customer communications to achieve streamlined agile content and efficient operations while maintaining data privacy. To address these needs, Topdown has developed the INTOUCH SaaS CCM solution, an innovative cloud-based approach to CCM for sharing data, content and processes across organizations that transforms communications operations.

“As a not-for-profit insurance company in a regulated environment, we have a strategic goal to treat our customers how we expect to be treated. We are constantly exploring and evolving ways to exceed our customers’ expectations. We have a hard-earned reputation for service excellence. The smart automation and flexible integration platform of the Topdown INTOUCH solution will immediately empower our customer relations team to manage content and improve our communications,” said Mike Downing, WPA’s Chief Technology Officer.

The simple, task-focused interface of INTOUCH enables non-IT resources to create CCM templates and rules-based workflows for centralized content and branding assets. INTOUCH provides enterprise-wide functionality for template consolidation and streamlined omnichannel content updates. Template development time is significantly reduced improving the speed to market and the opportunity to grow workload volume. INTOUCH provides the highest levels of data security and privacy for all stages of content whether it is stored, in-use or in-transit.

“Transforming CCM operations to a modern cloud-based platform enables enterprises to optimize efficiencies and improve communication effectiveness in a secure environment. We are delighted to work with WPA to advance their CCM strategies while reducing their dependency for IT resources. Our INTOUCH solution and team of CCM experts enable quick platform integrations and ease of use to discover immediate gains and opportunities for business expansion,” said Matt Lederer, SVP of Sales and Marketing, Topdown.

About Western Provident Association (WPA)
WPA helps their customers access the best care. With a heritage of more than 120 years, WPA looks after families, the self-employed, the professions, SME, large companies and Global Brands.

About Topdown
Topdown provides customer communication management software and services to organizations looking to provide the best possible customer experience during high-value customer journeys. For nearly 40 years, from the mainframe to the desktop and now to the cloud, Topdown has helped companies communicate more effectively and efficiently with their customers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:

WPA
Charlie MacEwan
Corporate Communications Director
charlie.macewan@wpa.org.uk
0044 - 7771 808083

Topdown
Mike Lui
Marketing
Mike.lui@topdownsystems.com
301-417-9660 ext. 181

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye